Acrow Limited has raised $16 million through an oversubscribed Share Purchase Plan, exceeding its $10 million underwriting target. The additional funds will be directed towards debt reduction, reinforcing the company’s financial position ahead of a pending placement approval.
- SPP oversubscribed with $21 million in applications
- Board accepts $16 million, $6 million above underwriting
- 18.8 million new shares issued at $0.85 each
- Funds earmarked for further debt repayment
- Tranche 2 placement pending shareholder approval
Oversubscribed Share Purchase Plan Raises $16 Million
Acrow Limited (ASX:ACF) has successfully closed its Share Purchase Plan (SPP), raising $16 million; significantly surpassing the $10 million underwriting target set by Morgans Corporate Limited and Shaw and Partners Limited. The SPP attracted approximately $21 million in valid applications from around 1,500 eligible shareholders, representing a participation rate of 21%, well above the underwritten amount.
In response to the strong demand, Acrow’s Board exercised its discretion to accept $6 million more than the underwritten sum, balancing shareholder support with prudent capital management. The company plans to apply these additional funds towards further debt repayment, aiming to strengthen its balance sheet ahead of continued growth initiatives.
Share Allocation and Scale Back Process
Approximately 18.8 million new fully paid ordinary shares will be issued at $0.85 each, matching the price of a recent placement. Due to the oversubscription, Acrow implemented a pro-rata scale back of applications based on shareholders’ relative holdings as of the SPP record date. Importantly, shareholders affected by scale back will still receive a minimum parcel of $1,000 worth of new shares.
Refunds for scaled-back applications will be processed promptly by direct credit or EFT, with shareholders notified of their final allocations in the coming days. The new shares are expected to be issued on 23 July 2026, with trading commencing on 27 July 2026.
Pending Shareholder Approval for Placement Tranche Two
While the SPP shares are issued without shareholder approval, Tranche 2 of Acrow’s recent two-tranche placement remains subject to approval at an Extraordinary General Meeting (EGM) scheduled for 29 July 2026. If approved, the second tranche shares are expected to be allotted and commence trading around 4 August 2026. Consequently, the underwriting arrangement for the SPP has been withdrawn, and the related resolution at the EGM has been removed.
This capital raising complements Acrow’s recent $70 million equity placement aimed at funding strategic acquisitions and expanding its footprint in the Australian construction sector. The company’s disciplined approach to capital management and debt reduction reflects ongoing efforts to solidify its financial position amid growth ambitions.
Bottom Line?
Acrow’s decision to accept oversubscription in its SPP signals strong shareholder confidence and a commitment to debt reduction, but the final impact hinges on upcoming shareholder approval for the placement’s second tranche.
Questions in the middle?
- Will the EGM approve the Tranche 2 placement without significant opposition?
- How will the additional capital raised influence Acrow’s debt metrics and credit profile?
- What market reaction will the scaled-back SPP allocations provoke among smaller shareholders?